Regeneron Pharmaceuticals is trading 4.2% up at $695.14 today, outperforming both the broader market and its biotech peers despite a lack of company-specific news.
- The gain appears driven by investor rotation and idiosyncratic buying interest rather than a defined catalyst.
- No fresh earnings, FDA decisions, or major analyst calls have emerged today to explain the move, which is particularly notable given the sector-wide weakness.